<DOC>
	<DOCNO>NCT02844088</DOCNO>
	<brief_summary>Meningococcus C vaccine first use France prevent epidemic . It success Puy-de-Dôme , Landes , Pyrénées Atlantiques Hautes Pyrénées . Following many European country , France introduce meningococcus C conjugate vaccine 2009 recommendation suffiicently apply ( 6,6 % 20-25 years-old vaccinated 2015 ) . The situation France different UK data subject . The vaccination campaign 2002 Puy-de-Dôme offer much detachment , possible comparison vaccinate unvaccinated people , among meningococcus circulation could maintain immunity . This reason decide ass 2016 vaccinal natural immunity among Puy-de-Dôme population .</brief_summary>
	<brief_title>Evaluation Vaccinal Natural Immunity Against Meningococcus C</brief_title>
	<detailed_description>People recruit hospitalisation consultation Pediatric , Occupational Medecine , Infectiology departments Clermont Ferrand Hospital Health Service Auvergne 's University , March September 2016 . Doctors give information study collect consent blood test do ( two tube 4,5mL ) . Blood test daily collect freeze . Then analyse Meningococcus National Reference Center , Paris .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>people 13 39 year old receive meningococcus C conjugate vaccine 2002 PuydeDôme ( vaccinate group ) ( unvaccinated group ) vaccination 2002 contain meningococcus C valence refusal participate</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>meningococcus C</keyword>
</DOC>